Catalysts for $PFE
643 tracked
Sep 26, 2025
device recall
ASP Global, LLC. dba Anatomy Supply Partners, LLC. device recall (Cls II)
PFIZER INC
→
Sep 24, 2025
approval
HEPARIN SODIUM — FDA approval
HEPARIN SODIUM
→
Sep 23, 2025
approval
AZITHROMYCIN — FDA approval
PFIZER INC
→
Sep 20, 2025
grant
NOVAEEL, INC. — Stability Study Protocol for 0.1% Estradiol Type A Medicated Article (Estraqua?)
PFIZER INC
→
Sep 20, 2025
grant
NOVAEEL, INC. — Environmental Assessment of Estraqua? (Estradiol Type A Medical Article) for ...
PFIZER INC
→
Sep 18, 2025
grant
VIA THERAPEUTICS, LLC — Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatmen...
PFIZER INC
→
Sep 16, 2025
approval
HYMPAVZI (MARSTACIMAB-HNCQ) — FDA approval
marstacimab
→
Sep 15, 2025
grant
WEILL MEDICAL COLL OF CORNELL UNIV — Identifying Novel Roles and the Therapeutic Potential of the Thrombin Recepto...
PFIZER INC
→
Aug 27, 2025
recall
PFIZER INC recall (Cls II)
PFIZER INC
→
Aug 27, 2025
recall
PFIZER INC recall (Cls II)
PFIZER INC
→
Aug 20, 2025
recall
Pfizer recall (Cls II)
PFIZER INC
→
Aug 6, 2025
recall
Pfizer Inc. recall (Cls II)
PFIZER INC
→
Aug 6, 2025
recall
Pfizer Inc. recall (Cls II)
PFIZER INC
→
Aug 1, 2025
approval
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Jul 18, 2025
device pma
Ferrosan Meidcal Devices A/S — SURGIFLO® Hemostatic Matrix; SURGIFLO® Hemostatic Matrix Kit with Thrombin (PMA supplement)
PFIZER INC
→
Jul 10, 2025
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 9, 2025
device pma
Ferrosan Meidcal Devices A/S — SURGIFLO Hemostatic Matrix Kit with Thrombin (PMA supplement)
PFIZER INC
→
Jul 8, 2025
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 2, 2025
recall
Pfizer Inc. recall (Cls II)
PFIZER INC
→
Mar 21, 2025
approval
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 19, 2025
recall
Aspen Biopharma Labs Pvt., Ltd. recall (Cls II)
PFIZER INC
→
Feb 21, 2025
approval
XELJANZ (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Feb 21, 2025
approval
XELJANZ XR (TOFACITINIB CITRATE) — FDA approval
tofacitinib citrate ER
→
Feb 18, 2025
approval
LORBRENA (LORLATINIB) — FDA approval
lorlatinib
→
Feb 12, 2025
approval
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Jan 31, 2025
approval
UNASYN (AMPICILLIN SODIUM) — FDA approval
UNASYN
→
Jan 31, 2025
approval
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Jan 17, 2025
approval
ELELYSO (TALIGLUCERASE ALFA) — FDA approval
taliglucerase alfa
→
Dec 16, 2024
approval
DEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approval
medroxyprogesterone acetate
→
Dec 12, 2024
approval
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→